233 related articles for article (PubMed ID: 24752611)
1. Pancreastatin predicts survival in neuroendocrine tumors.
Sherman SK; Maxwell JE; O'Dorisio MS; O'Dorisio TM; Howe JR
Ann Surg Oncol; 2014 Sep; 21(9):2971-80. PubMed ID: 24752611
[TBL] [Abstract][Full Text] [Related]
2. It Is Time to Rethink Biomarkers for Surveillance of Small Bowel Neuroendocrine Tumors.
Tran CG; Sherman SK; Scott AT; Ear PH; Chandrasekharan C; Bellizzi AM; Dillon JS; O'Dorisio TM; Howe JR
Ann Surg Oncol; 2021 Feb; 28(2):732-741. PubMed ID: 32656719
[TBL] [Abstract][Full Text] [Related]
3. Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors.
Sherman SK; Maxwell JE; Carr JC; Wang D; Bellizzi AM; Sue O'Dorisio M; O'Dorisio TM; Howe JR
Clin Exp Metastasis; 2014 Dec; 31(8):935-44. PubMed ID: 25241033
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors.
Strosberg D; Schneider EB; Onesti J; Saunders N; Konda B; Shah M; Dillhoff M; Schmidt CR; Shirley LA
Ann Surg Oncol; 2018 Nov; 25(12):3613-3620. PubMed ID: 30182331
[TBL] [Abstract][Full Text] [Related]
5. Elevated Plasma Pancreastatin, but Not Chromogranin A, Predicts Survival in Neuroendocrine Tumors of the Duodenum.
Woltering EA; Beyer DT; Thiagarajan R; Ramirez RA; Wang YZ; Ricks MJ; Boudreaux JP
J Am Coll Surg; 2016 Apr; 222(4):534-42. PubMed ID: 26827125
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Factors Associated With Progression for Advanced-Stage/G1 and G2 Small-Bowel Neuroendocrine Tumors After Multimodal Therapy: Experience From a Tertiary Referral Center.
Khetan P; Oyewole F; Wolin E; Kim MK; Divino CM
Pancreas; 2020 Apr; 49(4):509-513. PubMed ID: 32224719
[TBL] [Abstract][Full Text] [Related]
7. Elevated Serum Pancreastatin Is an Indicator of Hepatic Metastasis in Patients With Small Bowel Neuroendocrine Tumors.
Khan TM; Garg M; Warner RR; Uhr JH; Divino CM
Pancreas; 2016 Aug; 45(7):1032-5. PubMed ID: 26684860
[TBL] [Abstract][Full Text] [Related]
8. Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database.
Fisher MD; Pulgar S; Kulke MH; Mirakhur B; Miller PJ; Walker MS; Schwartzberg LS
J Gastrointest Cancer; 2019 Dec; 50(4):816-823. PubMed ID: 30121904
[TBL] [Abstract][Full Text] [Related]
9. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors.
Dromain C; Pavel ME; Ruszniewski P; Langley A; Massien C; Baudin E; Caplin ME;
BMC Cancer; 2019 Jan; 19(1):66. PubMed ID: 30642293
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors.
Carr JC; Sherman SK; Wang D; Dahdaleh FS; Bellizzi AM; O'Dorisio MS; O'Dorisio TM; Howe JR
Ann Surg Oncol; 2013 Dec; 20 Suppl 3(0 3):S739-S746. PubMed ID: 24114056
[TBL] [Abstract][Full Text] [Related]
11. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
[TBL] [Abstract][Full Text] [Related]
12. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm.
Mirkin KA; Hollenbeak CS; Wong J
J Surg Res; 2017 May; 211():206-214. PubMed ID: 28501118
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of the preoperative main pancreatic duct dilation and neutrophil-to-lymphocyte ratio in pancreatic neuroendocrine tumors (PNETs) of the head after curative resection.
Zhou B; Zhan C; Xiang J; Ding Y; Yan S
BMC Endocr Disord; 2019 Nov; 19(1):123. PubMed ID: 31718651
[TBL] [Abstract][Full Text] [Related]
14. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
[TBL] [Abstract][Full Text] [Related]
15. Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study.
Lamarca A; Crona J; Ronot M; Opalinska M; Lopez Lopez C; Pezzutti D; Najran P; Carvhalo L; Franca Bezerra RO; Borg P; Vietti Violi N; Vidal Trueba H; de Mestier L; Schaefer N; Sundin A; Costa F; Pavel M; Dromain C;
Oncologist; 2019 Nov; 24(11):e1082-e1090. PubMed ID: 30910869
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors.
Mandair D; Khan MS; Lopes A; Furtado O'Mahony L; Ensell L; Lowe H; Hartley JA; Toumpanakis C; Caplin M; Meyer T
J Clin Endocrinol Metab; 2021 Mar; 106(3):872-882. PubMed ID: 33180939
[TBL] [Abstract][Full Text] [Related]
17. Hormone profiling, WHO 2010 grading, and AJCC/UICC staging in pancreatic neuroendocrine tumor behavior.
Morin E; Cheng S; Mete O; Serra S; Araujo PB; Temple S; Cleary S; Gallinger S; Greig PD; McGilvray I; Wei A; Asa SL; Ezzat S
Cancer Med; 2013 Oct; 2(5):701-11. PubMed ID: 24403235
[TBL] [Abstract][Full Text] [Related]
18. IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence.
Massironi S; Del Gobbo A; Cavalcoli F; Fiori S; Conte D; Pellegrinelli A; Milione M; Ferrero S
Endocrine; 2017 Nov; 58(2):360-367. PubMed ID: 28210937
[TBL] [Abstract][Full Text] [Related]
19. The Pancreas as a Site of Metastasis or Second Primary in Patients with Small Bowel Neuroendocrine Tumors.
Scott AT; Pelletier D; Maxwell JE; Sherman SK; Keck KJ; Li G; Dillon JS; O'Dorisio TM; Bellizzi AM; Howe JR
Ann Surg Oncol; 2019 Aug; 26(8):2525-2532. PubMed ID: 31011904
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
